COST EFFECTIVENESS OF DRUG-ELUTING STENTS VERSUS BARE METAL STENTS IN CLINICAL PRACTICE: EFFECT OF STENT LENGTH AND DIAMETER  by Schafer, Pascha et al.
E1184
JACC April 5, 2011
Volume 57, Issue 14
  QUALITY OF CARE AND OUTCOMES ASSESSMENT 
COST EFFECTIVENESS OF DRUG-ELUTING STENTS VERSUS BARE METAL STENTS IN CLINICAL 
PRACTICE: EFFECT OF STENT LENGTH AND DIAMETER
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-11:15 a.m.
Session Title: Cost-Effectiveness and Cost of Care
Abstract Category: 47. Appropriateness, Pay for Performance, Cost of Care
Session-Poster Board Number: 1034-140
Authors: Pascha Schafer, Matthew T. Sacrinty, Michael A. Kutcher, Renato M. Santos, Sanjay K. Gandhi, William C. Little, Robert J. Applegate, Wake 
Forest University School of Medicine, Winston-Salem, NC
Background:  Drug-eluting stents (DES) reduce the need for target vessel revascularization (TVR) versus bare metal stents (BMS). As health care 
costs come under closer scrutiny, however, the cost effectiveness of DES vs BMS is being questioned, particularly as a treatment strategy for all stent 
lengths and diameters.
Methods:  Three years of clinical follow-up and associated costs were available for 718 BMS and 769 DES single lesion intervention patients from 
the Wake Forest registry. We assessed costs of index stent, hospitalization for TVR, and clopidogrel. Incremental cost effectiveness ratios (ICERs) were 
calculated as the cost per TVR avoided to 3 years within stent length and diameter patient subgroups.
Results:  DES and BMS baseline patient and procedural characteristics were well matched. The higher index stent cost with DES was completely 
offset by reduced costs for TVR in almost all lesion length and diameter subgroups. Despite higher 3 year costs of clopidogrel for DES, the 3 year 
ICERs for DES vs BMS ranged from economically dominant to $13,783 per TVR avoided (see Table).
Conclusions:  Routine use of DES vs BMS for single lesion interventions resulted in costs <$10,000 per TVR avoided to 3 years in all stent 
diameter subgroups and all but the shortest stent length subgroup. Thus, despite the higher initial costs of DES their use is economically 
advantageous.
Three year cost and effect differences by length and diameter categories
Category
Index Stenting†
Δ Cost, $
Num Rpt Revasc
Avoided
(per 100 pts)
Rpt Revasc†
Δ Cost, $
Clopidogrel†
Δ Cost, $
Aggregate 3-Year†
Δ Cost, $
(95% CI)
3-Year
ICER‡
All single lesions 1349* 10.3 -1861* 793* 281 (-876 to 1374) $2,716
Stented length
≤18.0 mm
18.1 to 23.0 mm
>23.0 mm
1206*
1207*
1359*
7.8
11.5
13.7
-993
-2647*
-2649*
866*
737*
564*
1079 (-772 to 2946)
-703 (-3618 to 2152)
-725 (-2851 to 1344)
$13,783
<$0 (DOM)
<$0 (DOM)
Stent diameter
≤2.5 mm
2.6 to 3.0 mm
>3.0 mm
1249*
1394*
1340*
8.8
9.9
10.7
-1866
-1328
-2476*
580*
883*
828*
-37 (-2823 to 2474)
949 (-686 to 2673)
-307 (-2230 to 1711)
<$0 (DOM)
$9,272
<$0 (DOM)
* p<0.05
† All delta costs calculated as mean (DES) minus mean (BMS)
‡Cost per repeat revascularization avoided with DES
